

# SYMPOSIUM

## PLAQUETTES : UN RÔLE CENTRAL ET MÉCONNU DANS L'AVC



**Dr. J.-P. Desilles**

Fondation A. Rothschild  
Paris



**Pr. M. Mazighi**

Fondation A. Rothschild  
& Hôpital Lariboisière  
Paris



**Pr. S. Richard**


CHRU Nancy



# GLENZOCIMAB IN THE SETTING OF ACUTE ISCHEMIC STROKE

**Glenzocimab: antibody fragment targeting platelet glycoprotein VI**


- **ANTITHROMBOTIC ACTIVITY**
- **NO EFFECT on hemostasis = “no bleeding risk”**



## 1. ADD-ON EFFECT



- Glenzocimab inhibits the formation of platelet thrombi at site of fibrinolysis<sup>1,2</sup>
- Enhances recanalization



## 2. STAND-ALONE EFFECT


Glenzocimab acts on thrombo-inflammatory occlusion of the downstream microcirculation and consecutive hemorrhagic transformation<sup>3,4,5,6</sup>

3. Desilles, J.-P. *et al. J. Am. Heart Assoc.* **7**, (2018).
4. Bieber M. *et al. Exp. Neurol.* **344**, (2021)
5. Ng F. C. *et al. Neurology* **98**, (2022).
6. Desilles J.-P. *et al. Stroke* **46**, (2015).

1. Loyau et al. *Arterioscler Thomb Vasc Biol* **38**: 2626 (2018).
2. Ahmed M et al, *Arterioscler Thomb Vasc Biol*, **40**:2127 (2020)

# ACTIMIS trial

AIM : Evaluate the safety of glenzocimab within 4.5 hours of an AIS, in addition to recanalization procedures (IVT/MT)



**Primary Endpoint**

✓ **Safety:** serious adverse events (SAE), intracerebral hemorrhage (ICH)

**Key Secondary End Points**

**Efficacy**

- ✓ NIHSS at 24hrs
- ✓ mRS at Day 90

## Phase 1b:


- ✓ No increase in bleeding rate
- ✓ No dose-response relationship on safety
- ✓ PK similar to PK in healthy volunteers



**Good tolerance of glenzocimab 1000 mg in patients**  
**Selection as the fixed dose**

# ACTIMIS trial : Glenzocimab vs placebo

## Intracranial hemorrhages (Phase 1a & 2b)




## All-cause deaths (Phase 1a & 2b)



## Mechanical thrombectomy subgroup N=27/27

mTICI score	Glenzocimab n(%)	Placebo n(%)
2b/3	26 (96)	23 (85)
0-2a	1 (4)	4 (15)

## mRS shift at 90 days (Phase 2) MT patients \*



Glenzocimab administration is associated with:

- ✓ Reduction of intracranial hemorrhages, both symptomatic and asymptomatic
- ✓ Reduction in mortality
- ✓ *Post-hoc analysis* suggests an efficacy trend in patients treated with mechanical thrombectomy

# SYMPOSIUM

## PLAQUETTES : UN RÔLE CENTRAL ET MÉCONNU DANS L'AVC



**Dr. J.-P. Desilles**

Fondation A. Rothschild  
Paris



**Pr. M. Mazighi**

Fondation A. Rothschild  
& Hôpital Lariboisière  
Paris




**Pr. S. Richard**

CHRU Nancy




# Thrombose lors d'un AVC ischémique aigu




## Thrombose microvasculaire

Hypoxémie  
Ralentissement  
circulatoire  
Ischémie cellulaire






## Thrombus causal











**Microcirculation cérébrale**

# Thrombo-inflammation microvasculaire











**D** During MCA occlusion



1 hour after  
recanalization

24 hours after  
recanalization


NG





HG



# Mécanisme d'action de Glenzocimab



# Rôle de GP VI plaquettaire dans la thromboinflammation






# ACTICOR BIOTECH



[acticor-biotech.com](https://www.acticor-biotech.com)



16-18 NOV. 2022  
PALAIS DES CONGRÈS DIJON

27<sup>ES</sup> JOURNÉES DE LA SOCIÉTÉ FRANÇAISE DE NEURO-VASCULAIRE

